









市場行情
/
股票
/
nasdaq-adap
/

Adaptimmune Therapeutics PLC

ADAP

0.055USD

0.000

收盤 12/19, 16:00（美東）報價延遲15分鐘

87.31M總市值

虧損本益比TTM



Adaptimmune Therapeutics PLC

0.055

0.000

概覽公司財務分析

概覽

公司

財務

分析

關於 Adaptimmune Therapeutics PLC 公司

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Adaptimmune Therapeutics PLC簡介



公司代碼ADAP

公司名稱Adaptimmune Therapeutics PLC

上市日期May 06, 2015

CEORawcliffe (Adrian George)

員工數量506

證券類型Depository Receipt

年結日May 06

公司地址60 Jubilee Avenue

城市ABINGDON

上市交易所NASDAQ Capital Market Consolidated

國家United Kingdom

郵編OX14 4RX

電話441235430000

網址https://www.adaptimmune.com/

公司代碼ADAP

上市日期May 06, 2015

CEORawcliffe (Adrian George)

Adaptimmune Therapeutics PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Garry E. Menzel, Ph.D.

Non-Executive Independent Director

611.22K

+191.15%

Mr. Lawrence M. (Larry) Alleva, CPA

Non-Executive Independent Director

23.89K

Mr. Christopher Hill

Chief Financial Officer

Mr. Adrian Rawcliffe

Chief Executive Officer, Director

Mr. William C. (Bill) Bertrand, Jr., Esq.

Chief Operating Officer

Mr. John P. Furey

Non-Executive Independent Director

Dr. Ali Behbahani, M.D.

Non-Executive Independent Director

Mr. David M. (Dave) Mott

Non-Executive Independent Chairman of the Board

Dr. Andrew Allen, M.D., Ph.D.

Non-Executive Independent Director

Dr. Kristen M. Hege, M.D.

Non-Executive Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Garry E. Menzel, Ph.D.

Non-Executive Independent Director

611.22K

+191.15%

Mr. Lawrence M. (Larry) Alleva, CPA

Non-Executive Independent Director

23.89K

Mr. Christopher Hill

Chief Financial Officer

Mr. Adrian Rawcliffe

Chief Executive Officer, Director

Mr. William C. (Bill) Bertrand, Jr., Esq.

Chief Operating Officer

Mr. John P. Furey

Non-Executive Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Long Focus Capital Management LLC

7.01%

UBS Financial Services, Inc.

2.47%

Renaissance Technologies LLC

1.53%

Morgan Stanley & Co. LLC

1.38%

Jane Street Capital, L.L.C.

1.06%

其他

86.56%

持股股東

佔比

Long Focus Capital Management LLC

7.01%

UBS Financial Services, Inc.

2.47%

Renaissance Technologies LLC

1.53%

Morgan Stanley & Co. LLC

1.38%

Jane Street Capital, L.L.C.

1.06%

其他

86.56%

股東類型

持股股東

佔比

Hedge Fund

8.54%

Investment Advisor

3.42%

Research Firm

2.99%

Investment Advisor/Hedge Fund

0.84%

Individual Investor

0.63%

Pension Fund

0.07%

Bank and Trust

0.05%

Venture Capital

0.04%

其他

83.43%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

165

42.25M

57.79%

-8.12K

2025Q3

183

42.26M

58.51%

-57.25M

2025Q2

189

116.07M

65.05%

-1.37M

2025Q1

186

117.46M

62.78%

-44.42M

2024Q4

186

127.90M

58.86%

-11.67M

2024Q3

189

154.60M

64.35%

-2.20M

2024Q2

192

156.54M

67.34%

-7.97M

2024Q1

203

164.83M

67.18%

-6.80M

2023Q4

199

145.59M

71.95%

-5.54M

2023Q3

217

150.77M

70.44%

+3.59M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Long Focus Capital Management LLC

23.76M

8.96%

Jun 30, 2025

Renaissance Technologies LLC

1.88M

0.71%

+69.00K

+3.80%

Jun 30, 2025

Morgan Stanley & Co. LLC

4.22M

1.59%

+1.59M

+60.49%

Jun 30, 2025

Acadian Asset Management LLC

1.96M

0.74%

-254.07K

-11.45%

Jun 30, 2025

BofA Global Research (US)

1.14M

0.43%

-5.30K

-0.46%

Jun 30, 2025

Alpha Architect, LLC

800.00K

0.3%

+800.00K

Jun 30, 2025

Menzel (Garry E)

611.22K

0.23%

+401.29K

+191.15%

Apr 11, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ActivePassive International Equity ETF

Fidelity Enhanced Small Cap ETF

SPDR S&P International Small Cap ETF

Invesco NASDAQ Future Gen 200 ETF

SPDR Portfolio Developed World ex-US ETF

ActivePassive International Equity ETF

佔比0%

Fidelity Enhanced Small Cap ETF

佔比0%

SPDR S&P International Small Cap ETF

佔比0%

Invesco NASDAQ Future Gen 200 ETF

佔比0%

SPDR Portfolio Developed World ex-US ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Adaptimmune Therapeutics PLC的前五大股東是誰？



Adaptimmune Therapeutics PLC的前五大股東如下：
Long Focus Capital Management LLC
持有股份：23.76M
佔總股份比例：8.96%。
Renaissance Technologies LLC
持有股份：1.88M
佔總股份比例：0.71%。
Morgan Stanley & Co. LLC
持有股份：4.22M
佔總股份比例：1.59%。
Acadian Asset Management LLC
持有股份：1.96M
佔總股份比例：0.74%。
BofA Global Research (US)
持有股份：1.14M
佔總股份比例：0.43%。